Viewing Study NCT06548412


Ignite Creation Date: 2025-12-26 @ 11:07 AM
Ignite Modification Date: 2026-01-13 @ 6:38 PM
Study NCT ID: NCT06548412
Status: RECRUITING
Last Update Posted: 2025-07-25
First Post: 2024-08-08
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: CTX-009 With Gemcitabine, Cisplatin, and Durvalumab as First-line Therapy in Patients With Unresectable or Metastatic Biliary Tract Cancers
Sponsor: M.D. Anderson Cancer Center
Organization:

Study Modules

Identification Module Status Module Sponsor Collaborators Module Oversight Module Description Module Conditions Module Design Module Arms Interventions Module Outcomes Module Eligibility Module Contacts Locations Module References Module